“Due to significant reductions in demand for these products, the company has decided to cease operations at the plant,” the ...
The essential thrombocythemia market is on a growth trajectory, driven by increasing diagnosis rates, aging population ...
On March 13, 2025, the Federal Circuit decided in Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (No. 2023-2254) how ...
NICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro in a final decision, after the company undercut rivals from the same class.
SPONSOR PROFILE: About MSD Merck Sharp and Dohme (MSD) is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, MSD discovers, develops, ...
Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) ...
NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country - although it has had to drop a 2025 target date because ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results